Navigation Links
Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2008 Financial Results on Monday, May 12, at 8:30 A.M. EDT
Date:5/8/2008

NEW YORK, May 8 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) will hold a conference call on Monday, May 12, 2008 at 8:30 a.m. EDT to discuss the first quarter 2008 financial results. Michael S. Weiss, Chairman and Chief Executive Officer of the Company, will host the call. Keryx will announce its financial results for this period in a press release to be issued prior to the call.

In order to participate in the conference call, please call 1-800-723-6575 (U.S.), 1-785-830-1997 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a period of 15 days after the call.

The press release announcing our financial results for this period will be posted on the Company's website, http://www.keryx.com, prior to the call.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, or ESRD. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also mod
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Keryx Biopharmaceuticals to Present at the Deutsche Bank 33rd Annual Health Care Conference
2. Keryx Biopharmaceuticals Receives Nasdaq Notification
3. Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
4. Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference
5. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
7. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
8. Keryx Biopharmaceuticals Announces Additions to Management Team
9. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
10. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
11. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... MA (PRWEB) September 02, 2014 ... today the signage of a distribution agreement with ... is now distributing Myriant’s bio-succinic acid in the ... and Ireland, targeting customers in the industrial and ... distribution powerhouse, Azelis offers a far-reaching chemical portfolio ...
(Date:9/2/2014)... Inc. (Nasdaq: ONTY ) announced today that ... present at the Rodman & Renshaw 16 th Annual ... on Tuesday, Sept. 9, 2014 at 2:05 p.m. Eastern. ... will be accessible by visiting the Oncothyreon website www.oncothyreon.com ... About Oncothyreon Oncothyreon is a biotechnology company ...
(Date:9/2/2014)... 2014  Spherix Incorporated (SPEX) -- an intellectual property development company ... today announced that the United States Patent & Trademark ... the month of August that are part of a ... issued patents are: , U.S.RE45,065 issued ... 2014; and , U.S.RE45,095 issued August 26, 2014.  ...
(Date:9/1/2014)... The global oligonucleotide synthesis market is expected ... million in 2014, growing at a CAGR of ... synthesis market is categorized on the basis of ... The synthesized oligonucleotides segment is expected to register ... market during the forecast period, owing to an ...
Breaking Biology Technology:Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2United States Patent & Trademark Office Issues Three New Standard Essential Patents to Spherix 29.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 29.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 39.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 49.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 5
... Mass., Sept. 19 Boston Scientific,Corporation (NYSE: BSX ... Life,Sciences Conference, which is being held September 22 - ... Chief Executive Officer, will make a,30-minute presentation which will ... Thursday, September 25, beginning at approximately 9:00,a.m. ET., ...
... PARK, Ill., Sept. 19 Abbott (NYSE:,ABT) will announce ... before the market opens., The announcement will be ... at 8 a.m. Central time (9 a.m. Eastern), and ... http://www.abbottinvestor.com . An archived edition of the call will ...
... China, Sept. 19 /Xinhua-PRNewswire-FirstCall/ --,China-Biotics, Inc. (OTC ... Chinese firm specializing in the manufacture,research, development, ... that at its 2008 Annual General Meeting ... the Company,s nominees to the,Board of Directors., ...
Cached Biology Technology:China-Biotics, Inc. Announces Results of 2008 Annual General Meeting of Shareholders 2
(Date:9/2/2014)... distribution of media will have lower carbon emissions ... file sizes are large. , That,s the conclusion ... of Industrial Ecology that looked at the ... PlayStation3. Researchers found that Blu-ray Discs delivered via ... game files downloaded over broadband Internet. For their ...
(Date:9/2/2014)... New research suggests that professional baseball pitchers with poor core ... in a single season because of injury than are pitchers ... and pelvis. , In the study, 347 pitchers were assessed ... in their pelvis as they raised a leg to step ... at least 30 days cumulative, not consecutive during ...
(Date:9/2/2014)... new study published in the September issue of ... identifies a novel strategy to diagnose the leading ... irreversible structural damage has occurred. This advance involves ... on the endothelium of retinal vessels. Using new ... distinguish the early molecular development of diabetic retinopathy. ...
Breaking Biology News(10 mins):In pro baseball pitchers, weak core linked to more missed days 2In pro baseball pitchers, weak core linked to more missed days 3Molecular probes permit doctors to detect diabetic retinopathy before vision fails 2
... for hundreds of years as an herbal remedy to prevent ... commonly used herbal medicines in North America. However, in spite ... on the body,s immune system are conflicting. ... University Indianapolis are investigating the possibility that Echinacea has other ...
... 20 million people in the U.S., and many more worldwide, ... developing mesothelioma, a malignant cancer of the membranes that cover ... Moreover, asbestos exposure increases the risk of lung cancer among ... understand why asbestos causes cancer. The answer ...
... Tuesday 29 June 2010, announces this year,s award winners ... to theoretical physicist Professor Edward Witten for outstanding, transformative ... influential physicists of the past 30 years, he has ... particle physics and cosmology to theoretical areas of string ...
Cached Biology News:Mystery unraveled: How asbestos causes cancer 2IOP announces 2010 award winners 2